Similar Search Results

Designing SEP Licensing Negotiation Groups to Reduce Patent Holdout in 5G/IoT Markets

Peters, Ruud; Nikolic, Igor; Heiden, Bowman - 2022

In response to concerns that inefficiencies in SEP licensing may have a negative systemic impact on the development of emerging 5G and IoT Markets, the European Commission (EC) convened an Expert Group on Licensing and Valuation of Standards Essential Patents (SEP Expert Group), resulting in a...

Persistent link: https://www.econbiz.de/10013298253

A Theory of Socially-Inefficient Patent Holdout

Llobet, Gerard; Padilla, Atilano Jorge - 2022

This paper proposes a framework to analyze holdout in patent licensing negotiations. We show that when the validity of a patent is probabilistic, a potentialdownstream user has incentives to shun to pay the price offered by a patent holderto license the technology and risk being brought to...

Persistent link: https://www.econbiz.de/10013307288

The Value of Standard Essential Patents and the Level of Licensing

Heiden, Bowman; Padilla, Jorge; Peters, Ruud - 2020

This paper argues that the value of standard essential patents (SEPs) should be independent of the level of licensing in the value chain. We further argue the value of enabling technologies, such as SEPs, is best determined in relation to the value it produces to the consumer or end-user,...

Persistent link: https://www.econbiz.de/10014091531

Investment and patent licensing in the value chain

Llobet, Gerard; Neven, Damien J. - 2022

At which stage in the production chain should patent licensing takes place? In this paper we show that under realistic circumstances a patent holder would be better off by licensing downstream. This occurs when the licensing revenue can depend on the downstream value of the product either...

Persistent link: https://www.econbiz.de/10013536319

Institutioneller Wandel in Innovationssystemen : eine vergleichende Untersuchung der japanischen Pharma- und Halbleiterforschung

Philipsenburg, Gisela - 2005 - 1. Aufl.

Persistent link: https://www.econbiz.de/10002553495

Essays on Government Policy and Pharmaceutical Innovation - Dissertation Executive Summary

Blume-Kohout, Margaret - 2010

New drug therapies may deliver many social and economic benefits, but current levels of innovation across diseases may …

Persistent link: https://www.econbiz.de/10014195493

The Invention of an Investment Incentive for Pharmaceutical Innovation

Basheer, Shamnad - 2015

innovation. This sentiment stems, in large part, from the belief that pharmaceutical research and development (R&D) entails …

Persistent link: https://www.econbiz.de/10014161723

Patents, Partnerships, and the Pre-Competitive Collaboration Myth in Pharmaceutical Innovation

Vertinsky, Liza - 2015

Public-private partnerships offer a promising alternative paradigm for pharmaceutical innovation in complex disease … essential to accelerate pharmaceutical innovation. Patents threaten the potential of partnership strategies, however, by making … innovation is fundamentally flawed for two reasons. First, it ignores the competitive market pressures that both shape what is …

Persistent link: https://www.econbiz.de/10014136820

Pharmaceutical Innovation

Scherer, Frederic M. - 2014

This article, written for the forthcoming Handbook of the Economics of Technical Change, surveys the costs, risks, and challenges encountered in the discovery and development of superior new pharmaceuticals. The changing methods by which drugs are discovered, the links between companies and...

Persistent link: https://www.econbiz.de/10014058289

Pharmaceutical innovation collaboration, evaluation, and matching

Liu, Qianshuo - In: Journal of health economics 98 (2024), pp. 1-21

Persistent link: https://www.econbiz.de/10015182090